Clinical Trials Directory

Trials / Completed

CompletedNCT04873206

Diagnostic and Prognostic Value of PTEN Expression in Functional and Pathological Endometrial Biopsies

Diagnostic and Prognostic Value of PTEN Expression in Functional and Pathological Endometrial Biopsies.

Status
Completed
Phase
Study type
Observational
Enrollment
80 (actual)
Sponsor
Sohag University · Academic / Other
Sex
Female
Age
15 Years
Healthy volunteers
Accepted

Summary

endometrial hyperplasia may progress to endometrial adenocarcinoma. the exact possibility of such progression is not determined. there a need to detect biological markers that can help in detecting high risk cases of patients with endometrial hyperplasia that may progress to endometrial adenocarcinoma. PTEN is a tumor suppressor gene that inhibit cell migration, proliferation and may induce apoptosis in damaged cells. variable expression of PTEN in functional, hyperplastic and neoplastic endometrial tissues may be of great help in detecting cases of hyperplasia that may progress to endometrial adenocarcinoma.

Detailed description

Adenocarcinoma of the endometrium is the most prevalent invasive tumor of female genital tract. Endometrial carcinoma is divided to 2 different types as regards to genitical and phenotypical features, type I endometrial carcinoma represents more than three quarters of all cases. Type I is inevitably preceded by hyperplastic changes in the endometrium. However, the malignant potential of endometrial hyperplasia to carcinoma is markedly variable and subjected to interobserver variations. Determine of novel biological markers for detection of precancerous endometrial hyperplasia that may proceed to endometrial adenocarcinoma is a must. PTEN is a tumor suppressor gene. it inhibits cell mitosis and migration. PTEN induce the damaged cells to pass in apoptosis. Low levels of PTEN expression noted in many human malignancies as melanoma, mammary and ovarian carcinomas. The aim of this study is to evaluate the expression of PTEN (by immunohistochemistry) in different endometrial biological conditions as endometrial hyperplasia and primary endometrial adenocarcinoma specimens, and correlate that expression to PTEN expression in physiological endometrial specimens.

Conditions

Interventions

TypeNameDescription
OTHERroutine stain by H&E.formalin fixed, Parraffin embedded endometrial tissues will be sectioned and get stained by the routine Haematoxalin and Eosin stain in addition to immunohistochemical staining by anti-human PTEN antibody.

Timeline

Start date
2020-01-01
Primary completion
2020-06-30
Completion
2020-12-31
First posted
2021-05-05
Last updated
2022-07-15

Locations

1 site across 1 country: Egypt

Source: ClinicalTrials.gov record NCT04873206. Inclusion in this directory is not an endorsement.